Malte Tiburcy

Overview
Related items

About Malte Tiburcy:

No description specified

SEEK ID: https://goeseek.gwdguser.de/people/16

Location: Germany

ORCID: https://orcid.org/0000-0002-6942-6275

Expertise: Not specified

Tools: Not specified

Their tags

This person has not yet tagged anything.

Related items

Advanced Programmes list for this Person with search and filtering

Sonderforschungsbereiche/Collaborative Research Centers

No description specified

Projects: CRC1002: Modulatory Units in Heart Failure, TRR 274: Checkpoints of Central Nervous System Recovery, SFB 1190: Compartmental Gates and Contact Sites in Cells

Web page: Not specified

Advanced Projects list for this Person with search and filtering

CRC1002: Modulatory Units in Heart Failure

https://sfb1002.med.uni-goettingen.de/ (Research Data Platform) https://gepris.dfg.de/gepris/projekt/193793266?language=en (DFG Gepris entry) With a prevalence of between two and four percent, heart failure remains one of the most common diseases in Europe. Although tremendous progress has been made in its treatment, the morbidity and mortality of affected patients remains high. Advanced heart failure can still only be treated palliatively.We define modulatory units as cell-based and/or genetic ...

Programme: Sonderforschungsbereiche/Collaborative Research Centers

Public web page: https://herzzentrum.umg.eu/forschung/forschungsverbuende/sfb-1002/

Start date: 1st Jul 2012

End date: 30th Jun 2024

Organisms: Human, Mouse

Advanced Institutions list for this Person with search and filtering

University Medical Center Göttingen

Country: Germany

City: Göttingen

Web page: https://ror.org/021ft0n22

Advanced Investigations list for this Person with search and filtering

1 hidden item

Advanced Studies list for this Person with search and filtering

4 hidden items

Advanced Assays list for this Person with search and filtering

3 hidden items

Advanced Data files list for this Person with search and filtering

4 hidden items

Advanced Publications list for this Person with search and filtering

Engineered skeletal muscle recapitulates human muscle development, regeneration and dystrophy.

CRC1002: Modulatory Units in Heart Failure

Abstract (Expand)

BACKGROUND: Human pluripotent stem cell-derived muscle models show great potential for translational research. Here, we describe developmentally inspired methods for the derivation of skeletal muscle … cells and their utility in skeletal muscle tissue engineering with the aim to model skeletal muscle regeneration and dystrophy in vitro. METHODS: Key steps include the directed differentiation of human pluripotent stem cells to embryonic muscle progenitors followed by primary and secondary foetal myogenesis into three-dimensional muscle. To simulate Duchenne muscular dystrophy (DMD), a patient-specific induced pluripotent stem cell line was compared to a CRISPR/Cas9-edited isogenic control line. RESULTS: The established skeletal muscle differentiation protocol robustly and faithfully recapitulates critical steps of embryonic myogenesis in two-dimensional and three-dimensional cultures, resulting in functional human skeletal muscle organoids (SMOs) and engineered skeletal muscles (ESMs) with a regeneration-competent satellite-like cell pool. Tissue-engineered muscle exhibits organotypic maturation and function (up to 5.7 +/- 0.5 mN tetanic twitch tension at 100 Hz in ESM). Contractile performance could be further enhanced by timed thyroid hormone treatment, increasing the speed of contraction (time to peak contraction) as well as relaxation (time to 50% relaxation) of single twitches from 107 +/- 2 to 75 +/- 4 ms (P < 0.05) and from 146 +/- 6 to 100 +/- 6 ms (P < 0.05), respectively. Satellite-like cells could be documented as largely quiescent PAX7(+) cells (75 +/- 6% Ki67(-) ) located adjacent to muscle fibres confined under a laminin-containing basal membrane. Activation of the engineered satellite-like cell niche was documented in a cardiotoxin injury model with marked recovery of contractility to 57 +/- 8% of the pre-injury force 21 days post-injury (P < 0.05 compared to Day 2 post-injury), which was completely blocked by preceding irradiation. Absence of dystrophin in DMD ESM caused a marked reduction of contractile force (-35 +/- 7%, P < 0.05) and impaired expression of fast myosin isoforms resulting in prolonged contraction (175 +/- 14 ms, P < 0.05 vs. gene-edited control) and relaxation (238 +/- 22 ms, P < 0.05 vs. gene-edited control) times. Restoration of dystrophin levels by gene editing rescued the DMD phenotype in ESM. CONCLUSIONS: We introduce human muscle models with canonical properties of bona fide skeletal muscle in vivo to study muscle development, maturation, disease and repair.

Authors: M. Shahriyari, M. R. Islam, S. M. Sakib, M. Rinn, A. Rika, D. Kruger, L. Kaurani, V. Gisa, M. Winterhoff, H. Anandakumar, O. Shomroni, M. Schmidt, G. Salinas, A. Unger, W. A. Linke, J. Zschuntzsch, J. Schmidt, R. Bassel-Duby, E. N. Olson, A. Fischer, W. H. Zimmermann, M. Tiburcy

Date Published: 19th Oct 2022

Publication Type: Journal

PubMed ID: 36254806

Citation: J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):3106-3121. doi: 10.1002/jcsm.13094. Epub 2022 Oct 18.

Created: 26th May 2023 at 11:43

Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy.

CRC1002: Modulatory Units in Heart Failure

(Show All)

Abstract (Expand)

BACKGROUND: Noonan syndrome (NS) is a multisystemic developmental disorder characterized by common, clinically variable symptoms, such as typical facial dysmorphisms, short stature, developmental delay, … intellectual disability as well as cardiac hypertrophy. The underlying mechanism is a gain-of-function of the RAS-mitogen-activated protein kinase signaling pathway. However, our understanding of the pathophysiological alterations and mechanisms, especially of the associated cardiomyopathy, remains limited and effective therapeutic options are lacking. METHODS: Here, we present a family with two siblings displaying an autosomal recessive form of NS with massive hypertrophic cardiomyopathy as clinically the most prevalent symptom caused by biallelic mutations within the leucine zipper-like transcription regulator 1 (LZTR1). We generated induced pluripotent stem cell-derived cardiomyocytes of the affected siblings and investigated the patient-specific cardiomyocytes on the molecular and functional level. RESULTS: Patients' induced pluripotent stem cell-derived cardiomyocytes recapitulated the hypertrophic phenotype and uncovered a so-far-not-described causal link between LZTR1 dysfunction, RAS-mitogen-activated protein kinase signaling hyperactivity, hypertrophic gene response and cellular hypertrophy. Calcium channel blockade and MEK inhibition could prevent some of the disease characteristics, providing a molecular underpinning for the clinical use of these drugs in patients with NS, but might not be a sustainable therapeutic option. In a proof-of-concept approach, we explored a clinically translatable intronic CRISPR (clustered regularly interspaced short palindromic repeats) repair and demonstrated a rescue of the hypertrophic phenotype. CONCLUSIONS: Our study revealed the human cardiac pathogenesis in patient-specific induced pluripotent stem cell-derived cardiomyocytes from NS patients carrying biallelic variants in LZTR1 and identified a unique disease-specific proteome signature. In addition, we identified the intronic CRISPR repair as a personalized and in our view clinically translatable therapeutic strategy to treat NS-associated hypertrophic cardiomyopathy.

Authors: U. Hanses, M. Kleinsorge, L. Roos, G. Yigit, Y. Li, B. Barbarics, I. El-Battrawy, H. Lan, M. Tiburcy, R. Hindmarsh, C. Lenz, G. Salinas, S. Diecke, C. Muller, I. Adham, J. Altmuller, P. Nurnberg, T. Paul, W. H. Zimmermann, G. Hasenfuss, B. Wollnik, L. Cyganek

Date Published: 15th Sep 2020

Publication Type: Journal

PubMed ID: 32623905

Citation: Circulation. 2020 Sep 15;142(11):1059-1076. doi: 10.1161/CIRCULATIONAHA.119.044794. Epub 2020 Jul 6.

Created: 30th May 2023 at 14:27

CRISPLD1: a novel conserved target in the transition to human heart failure.

CRC1002: Modulatory Units in Heart Failure

Abstract (Expand)

Heart failure is a major health problem worldwide with a significant morbidity and mortality rate. Although studied extensively in animal models, data from patients at the compensated disease stage are …

Authors: S. Khadjeh, V. Hindmarsh, F. Weber, L. Cyganek, R. O. Vidal, S. Torkieh, K. Streckfuss-Bomeke, D. Lbik, M. Tiburcy, B. A. Mohamed, S. Bonn, K. Toischer, G. Hasenfuss

Date Published: 7th Mar 2020

Publication Type: Journal

PubMed ID: 32146539

Citation: Basic Res Cardiol. 2020 Mar 7;115(3):27. doi: 10.1007/s00395-020-0784-4.

Created: 30th May 2023 at 12:34

(v.1.15.2)

About FAIRDOM | Funding and Programmes | Credits